NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results

Clin Adv Hematol Oncol. 2016 May;14(5 Suppl 7):8-9.
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Chemoradiotherapy
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Disease Progression
  • Humans
  • Intestinal Neoplasms / diagnosis
  • Intestinal Neoplasms / mortality
  • Intestinal Neoplasms / therapy*
  • Kaplan-Meier Estimate
  • Neuroendocrine Tumors / diagnosis
  • Neuroendocrine Tumors / mortality
  • Neuroendocrine Tumors / therapy*
  • Octreotide / administration & dosage
  • Octreotide / adverse effects
  • Octreotide / analogs & derivatives*
  • Octreotide / therapeutic use
  • Organometallic Compounds / administration & dosage
  • Organometallic Compounds / adverse effects
  • Organometallic Compounds / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Organometallic Compounds
  • lutetium Lu 177 dotatate
  • Octreotide